After evaluating the company's strategic options, including the sale of its U.K. business, monetizing its real estate, and a leveraged buyout, Jefferies analyst Brian Tanquilut believes "meaningful value" could be realized in Acadia Healthcare, even absent any near-term improvement in fundamentals. A divestiture of the U.K. business or a sale-leaseback could push Acadia shares to $46, Tanquilut tells investors in a research note. In a leveraged buyout, Acadia should command greater than $48 per share, the analyst contends. He views the company as a viable LBO candidate and keeps a Buy rating on the shares with a $42 price target.